Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Relmada Therapeutics, Inc. is one of them.

Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotech company that develops innovative therapies for oncology and central nervous system disorders. In 2025, the company will expand its pipeline with two Phase 2 candidates: NDV-01 for non-muscle invasive bladder cancer (NMIBC) and sepranolone for compulsivity disorders such as Prader-Willi Syndrome (PWS).

In September 2025, Relmada Therapeutics, Inc. (NASDAQ:RLMD) reported promising Phase 2 results for NDV-01, a sustained-release formulation of gemcitabine and docetaxel, showing a 91% complete response rate. The firm is preparing to launch a Phase 3 registrational trial in early 2026. Sepranolone is also progressing toward a Phase 2 trial for PWS, with regulatory and manufacturing steps underway. Additionally, the business regained compliance with Nasdaq’s minimum bid price requirement, ensuring continued listing and signaling market stability, placing it among the best penny stocks to watch in biotech.

Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data

On the financial side, Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted a $9.9 million net loss in Q2 2025 and held approximately $20.6 million in cash, reflecting a cautious cash position as it ramps up for larger clinical trials.

While we acknowledge the risk and potential of RLMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RLMD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.